References
- Sharma A, Liu H, Herwig-Carl MC, Chand Dakal T, Schmidt-Wolf IGH. Epigenetic regulatory enzymes: mutation prevalence and coexistence in cancers. Cancer Invest. 2021;39(3):257–273. doi:https://doi.org/10.1080/07357907.2021.1872593.
- Sun W, Yang J. Functional mechanisms for human tumor suppressors. J Cancer. 2010;1:136–140. doi:https://doi.org/10.7150/jca.1.136.
- Van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F, Matthijssens F, et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood. 2015;125(1):13–21. doi:https://doi.org/10.1182/blood-2014-05-577270.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:https://doi.org/10.3322/caac.21492.
- Nickerson ML, Dancik GM, Im KM, Edwards MG, Turan S, Brown J, et al. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Clin Cancer Res. 2014;20(18):4935–4938. doi:https://doi.org/10.1158/1078-0432.CCR-14-0330.
- Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007;129(7):1275–1286. doi:https://doi.org/10.1016/j.cell.2007.04.034.
- Koike K, Kasamatsu A, Iyoda M, Saito Y, Kouzu Y, Koike H, et al. High prevalence of epigenetic inactivation of the human four and a half LIM domains 1 gene in human oral cancer. Int J Oncol. 2013;42(1):141–150. doi:https://doi.org/10.3892/ijo.2012.1677.
- Sharma A, Jamil MA, Nuesgen N, Dauksa A, Gulbinas A, Schulz WA, et al. Detailed methylation map of LINE-1 5'-promoter region reveals hypomethylated CpG hotspots associated with tumor tissue specificity. Mol Genet Genomic Med. 2019;7(5):e601. doi:https://doi.org/10.1002/mgg3.601.
- Zhang H, Liao J, Zhang X, Zhao E, Liang X, Luo S, et al. Sex difference of mutation clonality in diffuse glioma evolution. Neuro Oncol. 2019;21(2):201–213. doi:https://doi.org/10.1093/neuonc/noy154.
- Sharma A, Biswas A, Liu H, Sen S, Paruchuri A, Katsonis P, et al. Mutational landscape of the BAP1 locus reveals an intrinsic control to regulate the miRNA network and the binding of protein complexes in uveal melanoma. Cancers (Basel). 2019;11(10):1600. doi:https://doi.org/10.3390/cancers11101600.
- Melzer C, Sharma A, Peters S, Aretz S, Biswas A, Holz FG, et al. Basal cell carcinomas developing independently from BAP1-tumor predisposition syndrome in a patient with bilateral uveal melanoma: diagnostic challenges to identify patients with BAP1-TPDS. Genes Chromosomes Cancer. 2019;58(6):357–364. doi:https://doi.org/10.1002/gcc.22724.
- Kreft L, Soete A, Hulpiau P, Botzki A, Saeys Y, De Bleser P. ConTra v3: a tool to identify transcription factor binding sites across species, update 2017. Nucleic Acids Res. 2017;45(W1):W490–W494. doi:https://doi.org/10.1093/nar/gkx376.
- Pomaznoy M, Ha B, Peters B. GOnet: a tool for interactive Gene Ontology analysis. BMC Bioinformatics. 2018;19(1):470. doi:https://doi.org/10.1186/s12859-018-2533-3.
- Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer. 2010;10(3):205–212. doi:https://doi.org/10.1038/nrc2795.
- Li W, Wang L, Katoh H, Liu R, Zheng P, Liu Y. Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers. Cancer Res. 2011;71(6):2162–2171. doi:https://doi.org/10.1158/0008-5472.CAN-10-3268.
- Brinton LA. Breast cancer risk among patients with Klinefelter syndrome. Acta Paediatr. 2011;100(6):814–815. doi:https://doi.org/10.1111/j.1651-2227.2010.02131.x.
- Kristiansen M, Langerød A, Knudsen GP, Weber BL, Børresen-Dale AL, Orstavik KH. High frequency of skewed X inactivation in young breast cancer patients. J Med Genet. 2002;39(1):30–33. doi:https://doi.org/10.1136/jmg.39.1.30.
- Liu R, Kain M, Wang L. Inactivation of X-linked tumor suppressor genes in human cancer. Future Oncol. 2012;8(4):463–481. doi:https://doi.org/10.2217/fon.12.26.
- Viuff MH, Stochholm K, Lin A, Berglund A, Juul S, Gravholt CH. Cancer occurrence in Turner syndrome and the effect of sex hormone substitution therapy. Eur J Endocrinol. 2021;184(1):79–88. doi:https://doi.org/10.1530/EJE-20-0702.
- Ji J, Zöller B, Sundquist J, Sundquist K. Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: a national cohort study. Int J Cancer. 2016;139(4):754–758. doi:https://doi.org/10.1002/ijc.30126.
- Sharma A, Reutter H, Ellinger J. DNA methylation and bladder cancer: where genotype does not predict phenotype. Curr Genomics. 2020;21(1):34–36. doi:https://doi.org/10.2174/1389202921666200102163422.
- Mugal CF, Arndt PF, Holm L, Ellegren H. Evolutionary consequences of DNA methylation on the GC content in vertebrate genomes. G3 (Bethesda). 2015;5(3):441–447. doi:https://doi.org/10.1534/g3.114.015545.
- Foltz G, Ryu GY, Yoon JG, Nelson T, Fahey J, Frakes A, et al. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res. 2006; 66(13):6665–6674. doi:https://doi.org/10.1158/0008-5472.CAN-05-4453.
- Meng Q, Zhi T, Chao Y, Nie E, Xu X, Shi Q, et al. Bex2 controls proliferation of human glioblastoma cells through NF-κB signaling pathway. J Mol Neurosci. 2014;53(2):262–270. doi:https://doi.org/10.1007/s12031-013-0215-1.
- Caragher SP, Shireman JM, Huang M, Miska J, Atashi F, Baisiwala S, et al. Activation of dopamine receptor 2 prompts transcriptomic and metabolic plasticity in glioblastoma. J Neurosci. 2019;39(11):1982–1993. doi:https://doi.org/10.1523/JNEUROSCI.1589-18.2018.
- Suwala AK, Koch K, Rios DH, Aretz P, Uhlmann C, Ogorek I, et al. Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma in vitro. Oncotarget. 2018;9(32):22703–22716. doi:https://doi.org/10.18632/oncotarget.25210.
- Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–231. doi:https://doi.org/10.1038/nature10833.
- Sharma A, Stei MM, Fröhlich H, Holz FG, Loeffler KU, Herwig-Carl MC. Genetic and epigenetic insights into uveal melanoma. Clin Genet. 2018;93(5):952–61. doi:https://doi.org/10.1111/cge.13136.
- Sharma A, Liu H, Tobar-Tosse F, Noll A, Chand Dakal T, Li H, et al. Genome organization in proximity to the BAP1 locus appears to play a pivotal role in a variety of cancers. Cancer Sci. 2020;111(4):1385–1391. doi:https://doi.org/10.1111/cas.14319.
- Chintalapati M, Moorjani P. Evolution of the mutation rate across primates. Curr Opin Genet Dev. 2020;62:58–64. doi:https://doi.org/10.1016/j.gde.2020.05.028.
- Liu H, Li H, Luo K, Sharma A, Sun X. Prognostic gene expression signature revealed the involvement of mutational pathways in cancer genome. J Cancer. 2020;11(15):4510–4520. doi:https://doi.org/10.7150/jca.40237.